MINNEAPOLIS, Nov. 25, 2015 /PRNewswire/ -- ARKRAY USA, Inc., a leader in diabetes care products, continues to provide evidence demonstrating the accuracy of its blood glucose meter systems. Last week at the World Congress on Insulin Resistance, Diabetes and Cardiovascular Disease in Los Angeles, studies showed that both the Company’s GLUCOCARD® 01 meter and the Assure® Prism multi-user meter met high accuracy requirements. The ability to accurately measure glucose levels in blood is essential for people afflicted with diabetes so they can effectively manage the disease, according to the American Diabetes Association (ADA).
The Assure Prism system was shown to meet stringent ISO 15197:2013 system accuracy performance criteria. The Assure Prism is designed for use by healthcare professionals who monitor diabetes patients in long-term care environments such as nursing homes.
The GLUCOCARD 01, designed for use by consumers, was shown to meet global accuracy performance criteria.
“ARKRAY’s ability to continuously validate the accuracy of our products demonstrates our commitment to provide accurate blood glucose meter systems to both healthcare professionals and consumers,” said ARKRAY USA President Jonathan Chapman. “ARKRAY is on the forefront of providing compelling clinical evidence that show ARKRAY products give users accurate readings that help them manage their diabetes.”
Diabetes, or diabetes mellitus, is a metabolic type of disease in which affected people have high blood glucose (blood sugar), either because insulin production is inadequate (Type 2), or because the islet cells in the pancreas no longer produce insulin (Type 1, sometimes referred to juvenile diabetes). People with untreated diabetes typically experience frequent urination, become increasingly thirsty and hungry. The ADA estimates that more than 30 million Americans suffer from either Type 1 or Type 2 diabetes and that 25.9% of American’s 65 years of age or greater will develop diabetes.
About ARKRAY USA, Inc.
ARKRAY USA, Inc. is a division of ARKRAY, a global leader in diabetes care with headquarters in Kyoto, Japan. For more than half a century, ARKRAY has pioneered products to ensure that people who have diabetes - and the health professionals who care for them - can better manage the condition. ARKRAY currently does business in more than 80 countries worldwide and is the market leader in diabetes management in the long-term care market in the U.S. The Company has a long history of developing cutting edge technology such as the first portable glucose analyzer available in the United States; the first HbA1C analyzer; and the first hand-held blood glucose meter. For more information, visit www.arkrayusa.com.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/accuracy-of-arkray-blood-glucose-meters-and-test-strips-demonstrated-in-studies-presented-at-world-diabetes-congress-300184563.html
SOURCE ARKRAY USA, Inc.
